Ocriplasmin (Thrombogenics) filed at FDA for Vitreomacular Adhesion. - 29-Dec-2011

Thrombogenics has submitted a biologics license application (BLA) to the FDA for ocriplasmin intravitreal injection 2.5mg/mL as a treatment for symptomatic Vitreomacular Adhesion, including macular hole, a progressive condition that if left untreated generally leads to significant visual distortion, deterioration in vision and in some cases central blindness. The condition affects about 500,000 people annually in the US and the European Union. Thrombogenics filed for the drug in the EU in October 2011.